<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217382</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0636</org_study_id>
    <nct_id>NCT04217382</nct_id>
  </id_info>
  <brief_title>Pre Transplantation Melanoma</brief_title>
  <acronym>MPG</acronym>
  <official_title>Pre Transplantation Melanoma : Retrospective and Prospective Multicenter Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melanoma incidence is increase in global population and number of transplantation also.&#xD;
      However immunosuppressor increase recurrence risk of melanoma.&#xD;
&#xD;
      There are more and more cases of eligible patients to transplant with an antecedent of&#xD;
      melanoma. There is no guideline yet.&#xD;
&#xD;
      Main objective is survival time without melanoma recurrence in this population to do&#xD;
      guideline of time limit or not between melanoma and transplantation by stage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">October 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 27, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>survival time without melanoma recurrence</measure>
    <time_frame>at enrollment</time_frame>
    <description>Delay in recurrence-free survival since diagnosis and since transplantation</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malignant Melanoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patient with melanoma pre transplantation</intervention_name>
    <description>survival time without melanoma recurrence</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient with an antecedent of melanoma before transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with an antecedent of melanoma before transplantation&#xD;
&#xD;
          -  Not opposite to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under the age of 18&#xD;
&#xD;
          -  patient under Guardianship&#xD;
&#xD;
          -  patient not affiliated with a health system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie DUCROUX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Dermatologie, HÃ´pital Edouard Herriot, Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie DUCROUX, MD</last_name>
    <phone>0472110324</phone>
    <phone_ext>+33</phone_ext>
    <email>Emilie.ducroux@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion PATRAS, Resident</last_name>
    <phone>0472110324</phone>
    <phone_ext>+33</phone_ext>
    <email>marion.patras@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>service de dermatologie - hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>emilie DUCROUX, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

